GOLDMAN SACHS GROUP INC - BRIDGEBIO PHARMA INC ownership

BRIDGEBIO PHARMA INC's ticker is BBIO and the CUSIP is 10806X102. A total of 169 filers reported holding BRIDGEBIO PHARMA INC in Q4 2020. The put-call ratio across all filers is 0.33 and the average weighting 0.7%.

Quarter-by-quarter ownership
GOLDMAN SACHS GROUP INC ownership history of BRIDGEBIO PHARMA INC
ValueSharesWeighting
Q3 2023$37,581,390
+113.1%
1,425,157
+39.0%
0.01%
+100.0%
Q2 2023$17,638,049
+9.1%
1,025,468
+5.2%
0.00%
+33.3%
Q1 2023$16,169,330
+56.6%
975,231
-28.0%
0.00%
+50.0%
Q4 2022$10,327,356
-14.1%
1,355,296
+12.0%
0.00%
-33.3%
Q3 2022$12,029,000
+38.6%
1,210,210
+26.7%
0.00%
+50.0%
Q2 2022$8,676,000
+18.3%
955,512
+32.2%
0.00%0.0%
Q1 2022$7,336,000
-38.3%
722,747
+1.4%
0.00%0.0%
Q4 2021$11,892,000
-59.0%
712,908
+15.3%
0.00%
-66.7%
Q3 2021$28,991,000
+10.2%
618,539
+43.3%
0.01%0.0%
Q2 2021$26,313,000
-29.6%
431,633
-28.8%
0.01%
-33.3%
Q1 2021$37,364,000
-16.1%
606,568
-3.2%
0.01%
-18.2%
Q4 2020$44,549,000
+108.6%
626,485
+10.0%
0.01%
+83.3%
Q3 2020$21,361,000
+75.4%
569,327
+52.4%
0.01%
+50.0%
Q2 2020$12,179,000
-1.8%
373,469
-12.7%
0.00%0.0%
Q1 2020$12,399,000
+56.5%
427,559
+89.1%
0.00%
+100.0%
Q4 2019$7,924,000
+116.0%
226,059
+32.3%
0.00%
+100.0%
Q3 2019$3,669,000
-1.7%
170,882
+23.5%
0.00%0.0%
Q2 2019$3,731,000138,3380.00%
Other shareholders
BRIDGEBIO PHARMA INC shareholders Q4 2020
NameSharesValueWeighting ↓
Aisling Capital Management LP 6,068,125$160,016,45665.94%
Kohlberg Kravis Roberts & Co. L.P. 31,060,971$819,077,80528.79%
Cormorant Asset Management, LP 4,662,530$122,950,9167.17%
Frazier Life Sciences Management, L.P. 2,725,949$71,883,2754.77%
Octagon Capital Advisors LP 971,639$25,622,1203.94%
M28 Capital Management LP 121,200$3,196,0443.66%
VIKING GLOBAL INVESTORS LP 25,120,991$662,440,5332.69%
BOONE CAPITAL MANAGEMENT LLC 313,381$8,263,8572.61%
Fernwood Investment Management, LLC 235,620$6,213,2992.23%
SOUTHPORT MANAGEMENT, L.L.C. 15,000$395,5502.15%
View complete list of BRIDGEBIO PHARMA INC shareholders